(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 2.98% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Gilead Sciences's revenue in 2025 is $28,863,000,000.On average, 7 Wall Street analysts forecast GILD's revenue for 2025 to be $35,547,301,602,075, with the lowest GILD revenue forecast at $35,266,846,978,079, and the highest GILD revenue forecast at $35,784,808,176,287. On average, 8 Wall Street analysts forecast GILD's revenue for 2026 to be $37,024,050,434,766, with the lowest GILD revenue forecast at $36,261,341,313,184, and the highest GILD revenue forecast at $38,425,308,574,688.
In 2027, GILD is forecast to generate $39,228,698,791,818 in revenue, with the lowest revenue forecast at $38,091,531,514,284 and the highest revenue forecast at $41,121,582,003,156.